دورية أكاديمية
أعرض في EDS

3 fraction pencil-beam scanning proton accelerated partial breast irradiation: early provider and patient reported outcomes of a novel regimen

التفاصيل البيبلوغرافية
العنوان: 3 fraction pencil-beam scanning proton accelerated partial breast irradiation: early provider and patient reported outcomes of a novel regimen
المؤلفون: Robert W. Mutter, Krishan R. Jethwa, Karthik Gonuguntla, Nicholas B. Remmes, Thomas J. Whitaker, Tina J. Hieken, Kathryn J. Ruddy, Lisa A. McGee, Kimberly S. Corbin, Sean S. Park
المصدر: Radiation Oncology, Vol 14, Iss 1, Pp 1-9 (2019)
بيانات النشر: BMC, 2019.
سنة النشر: 2019
المجموعة: LCC:Medical physics. Medical radiology. Nuclear medicine
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Abstract Background and purpose To report dosimetry and early adverse effects, aesthetic, and patient-reported outcomes of a prospective study of 3-fraction pencil-beam scanning (PBS) proton accelerated partial irradiation (APBI). Materials and methods Eligibility included women age ≥ 50 years with estrogen receptor positive (ER+), sentinel lymph node negative invasive or in-situ breast cancer measuring ≤2.5 cm. The prescription was 21.9 Gy (RBE 1.1) in 3 daily fractions to the post-operative tumor bed with a 1 cm expansion. Toxicities were collected using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, 10-point Linear Analog Scale Assessment, Patient-Reported Outcomes Version of the CTCAE, and the Harvard Breast Cosmesis Scale. Results Seventy-six women were treated between 2015 and 2017. The median breast volume receiving 50% of prescription or more was 28%. Median mean heart, mean ipsilateral lung, and maximum skin dose were 0 Gy, 0.1 Gy, and 20.6 Gy, respectively. With a median follow-up of 12 months, no treatment-related toxicity grade ≥ 2 has been observed. Most common grade 1 adverse events were dermatitis (68%) and skin hyperpigmentation (18%). At 12 months, the only persistent toxicities were one patient with grade 1 breast edema and one patient with a grade 1 seroma. 90% of patients reported quality of life as ≥7 out of 10 (0 indicating “as bad as it can be” and 10 indicating “as good as it can be”) and 98% of patients reported excellent or good cosmesis. Conclusion 3-fraction PBS proton APBI is well tolerated with low rates of physician and patient reported early adverse effects. Follow-up is ongoing to assess late toxicities and disease control outcomes. Further investigation of this novel adjuvant treatment strategy is warranted.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1748-717X
Relation: http://link.springer.com/article/10.1186/s13014-019-1417-7; https://doaj.org/toc/1748-717X
DOI: 10.1186/s13014-019-1417-7
URL الوصول: https://doaj.org/article/1884e9d6ecca4c0982928db7a283e7fd
رقم الأكسشن: edsdoj.1884e9d6ecca4c0982928db7a283e7fd
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:1748717X
DOI:10.1186/s13014-019-1417-7